(0.96%) 5 066.37 points
(0.92%) 38 251 points
(1.51%) 15 841 points
(0.18%) $79.14
(5.85%) $2.05
(0.25%) $2 316.80
(0.68%) $26.93
(1.12%) $965.60
(-0.10%) $0.932
(-0.39%) $10.99
(-0.10%) $0.798
(-1.40%) $91.96
5 days till quarter result
(amc 2024-05-07)
Expected move: +/- 5.02%
1.71% $ 39.97
@ $40.50
Wydano: 9 bal. 2024 @ 16:36
Zwrot: -1.31%
Poprzedni sygnał: bal. 8 - 19:23
Poprzedni sygnał:
Zwrot: 0.25 %
Live Chart Being Loaded With Signals
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally...
Stats | |
---|---|
Dzisiejszy wolumen | 373 886 |
Średni wolumen | 1.01M |
Kapitalizacja rynkowa | 5.08B |
EPS | $0 ( 2024-02-20 ) |
Następna data zysków | ( $0.690 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 19.03 |
ATR14 | $0.0240 (0.06%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-25 | Posard Matthew L. | Buy | 6 501 | Common Stock |
2024-04-25 | Posard Matthew L. | Buy | 8 804 | Option to Purchase Common Stock |
2024-04-25 | Miyashita Akiko Moni | Buy | 6 501 | Common Stock |
2024-04-25 | Miyashita Akiko Moni | Buy | 8 804 | Option to Purchase Common Stock |
2024-04-25 | Matsui Connie | Buy | 6 501 | Common Stock |
INSIDER POWER |
---|
29.82 |
Last 99 transactions |
Buy: 689 741 | Sell: 377 639 |
Wolumen Korelacja
Halozyme Therapeutics Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
LWAC | 0.957 |
SRAC | 0.91 |
NETE | 0.889 |
AMRB | 0.889 |
ACER | 0.853 |
HOUR | 0.849 |
KNSA | 0.839 |
MMAC | 0.831 |
EEIQ | 0.829 |
WBA | 0.829 |
10 Najbardziej negatywne korelacje | |
---|---|
TLGT | -0.945 |
SVAC | -0.942 |
GOODM | -0.919 |
SIBN | -0.88 |
RPHM | -0.88 |
PAIC | -0.872 |
SNPO | -0.86 |
MTSL | -0.85 |
PYXS | -0.845 |
XOG | -0.843 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Halozyme Therapeutics Inc Korelacja - Waluta/Towar
Halozyme Therapeutics Inc Finanse
Annual | 2023 |
Przychody: | $829.25M |
Zysk brutto: | $636.89M (76.80 %) |
EPS: | $2.13 |
FY | 2023 |
Przychody: | $829.25M |
Zysk brutto: | $636.89M (76.80 %) |
EPS: | $2.13 |
FY | 2022 |
Przychody: | $660.12M |
Zysk brutto: | $520.81M (78.90 %) |
EPS: | $1.480 |
FY | 2021 |
Przychody: | $443.31M |
Zysk brutto: | $361.90M (81.64 %) |
EPS: | $2.84 |
Financial Reports:
No articles found.
Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej